In vivo silencing of alpha-synuclein using naked siRNA

Jada Lewis, Heather L Melrose, David Bumcrot, Andrew Hope, Cynthia Zehr, Sarah Lincoln, Adam Braithwaite, Zhen He, Sina Ogholikhan, Kelly Hinkle, Caroline Kent, Ivanka Toudjarska, Klaus Charisse, Ravi Braich, Rajendra K. Pandey, Michael Heckman, Demetrius M. Maraganore, Juliana Crook, Matthew J. Farrer

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background: Overexpression of -synuclein (SNCA) in families with multiplication mutations causes parkinsonism and subsequent dementia, characterized by diffuse Lewy Body disease post-mortem. Genetic variability in SNCA contributes to risk of idiopathic Parkinson's disease (PD), possibly as a result of overexpression. SNCA downregulation is therefore a valid therapeutic target for PD. Results: We have identified human and murine-specific siRNA molecules which reduce SNCA in vitro. As a proof of concept, we demonstrate that direct infusion of chemically modified (naked), murine-specific siRNA into the hippocampus significantly reduces SNCA levels. Reduction of SNCA in the hippocampus and cortex persists for a minimum of 1 week post-infusion with recovery nearing control levels by 3 weeks post-infusion. Conclusion: We have developed naked gene-specific siRNAs that silence expression of SNCA in vivo. This approach may prove beneficial toward our understanding of the endogenous functional equilibrium of SNCA, its role in disease, and eventually as a therapeutic strategy for -synucleinopathies resulting from SNCA overexpression.

Original languageEnglish (US)
Article number19
JournalMolecular Neurodegeneration
Volume3
Issue number1
DOIs
StatePublished - 2008

Fingerprint

alpha-Synuclein
Small Interfering RNA
Parkinson Disease
Hippocampus
Synucleins
Lewy Body Disease
Parkinsonian Disorders
Dementia
Down-Regulation
Mutation
Therapeutics
Genes
In Vitro Techniques

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Clinical Neurology
  • Molecular Biology

Cite this

Lewis, J., Melrose, H. L., Bumcrot, D., Hope, A., Zehr, C., Lincoln, S., ... Farrer, M. J. (2008). In vivo silencing of alpha-synuclein using naked siRNA. Molecular Neurodegeneration, 3(1), [19]. https://doi.org/10.1186/1750-1326-3-19

In vivo silencing of alpha-synuclein using naked siRNA. / Lewis, Jada; Melrose, Heather L; Bumcrot, David; Hope, Andrew; Zehr, Cynthia; Lincoln, Sarah; Braithwaite, Adam; He, Zhen; Ogholikhan, Sina; Hinkle, Kelly; Kent, Caroline; Toudjarska, Ivanka; Charisse, Klaus; Braich, Ravi; Pandey, Rajendra K.; Heckman, Michael; Maraganore, Demetrius M.; Crook, Juliana; Farrer, Matthew J.

In: Molecular Neurodegeneration, Vol. 3, No. 1, 19, 2008.

Research output: Contribution to journalArticle

Lewis, J, Melrose, HL, Bumcrot, D, Hope, A, Zehr, C, Lincoln, S, Braithwaite, A, He, Z, Ogholikhan, S, Hinkle, K, Kent, C, Toudjarska, I, Charisse, K, Braich, R, Pandey, RK, Heckman, M, Maraganore, DM, Crook, J & Farrer, MJ 2008, 'In vivo silencing of alpha-synuclein using naked siRNA', Molecular Neurodegeneration, vol. 3, no. 1, 19. https://doi.org/10.1186/1750-1326-3-19
Lewis J, Melrose HL, Bumcrot D, Hope A, Zehr C, Lincoln S et al. In vivo silencing of alpha-synuclein using naked siRNA. Molecular Neurodegeneration. 2008;3(1). 19. https://doi.org/10.1186/1750-1326-3-19
Lewis, Jada ; Melrose, Heather L ; Bumcrot, David ; Hope, Andrew ; Zehr, Cynthia ; Lincoln, Sarah ; Braithwaite, Adam ; He, Zhen ; Ogholikhan, Sina ; Hinkle, Kelly ; Kent, Caroline ; Toudjarska, Ivanka ; Charisse, Klaus ; Braich, Ravi ; Pandey, Rajendra K. ; Heckman, Michael ; Maraganore, Demetrius M. ; Crook, Juliana ; Farrer, Matthew J. / In vivo silencing of alpha-synuclein using naked siRNA. In: Molecular Neurodegeneration. 2008 ; Vol. 3, No. 1.
@article{d58fd70d61634f0ebd82e2fcdcb88c20,
title = "In vivo silencing of alpha-synuclein using naked siRNA",
abstract = "Background: Overexpression of -synuclein (SNCA) in families with multiplication mutations causes parkinsonism and subsequent dementia, characterized by diffuse Lewy Body disease post-mortem. Genetic variability in SNCA contributes to risk of idiopathic Parkinson's disease (PD), possibly as a result of overexpression. SNCA downregulation is therefore a valid therapeutic target for PD. Results: We have identified human and murine-specific siRNA molecules which reduce SNCA in vitro. As a proof of concept, we demonstrate that direct infusion of chemically modified (naked), murine-specific siRNA into the hippocampus significantly reduces SNCA levels. Reduction of SNCA in the hippocampus and cortex persists for a minimum of 1 week post-infusion with recovery nearing control levels by 3 weeks post-infusion. Conclusion: We have developed naked gene-specific siRNAs that silence expression of SNCA in vivo. This approach may prove beneficial toward our understanding of the endogenous functional equilibrium of SNCA, its role in disease, and eventually as a therapeutic strategy for -synucleinopathies resulting from SNCA overexpression.",
author = "Jada Lewis and Melrose, {Heather L} and David Bumcrot and Andrew Hope and Cynthia Zehr and Sarah Lincoln and Adam Braithwaite and Zhen He and Sina Ogholikhan and Kelly Hinkle and Caroline Kent and Ivanka Toudjarska and Klaus Charisse and Ravi Braich and Pandey, {Rajendra K.} and Michael Heckman and Maraganore, {Demetrius M.} and Juliana Crook and Farrer, {Matthew J.}",
year = "2008",
doi = "10.1186/1750-1326-3-19",
language = "English (US)",
volume = "3",
journal = "Molecular Neurodegeneration",
issn = "1750-1326",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - In vivo silencing of alpha-synuclein using naked siRNA

AU - Lewis, Jada

AU - Melrose, Heather L

AU - Bumcrot, David

AU - Hope, Andrew

AU - Zehr, Cynthia

AU - Lincoln, Sarah

AU - Braithwaite, Adam

AU - He, Zhen

AU - Ogholikhan, Sina

AU - Hinkle, Kelly

AU - Kent, Caroline

AU - Toudjarska, Ivanka

AU - Charisse, Klaus

AU - Braich, Ravi

AU - Pandey, Rajendra K.

AU - Heckman, Michael

AU - Maraganore, Demetrius M.

AU - Crook, Juliana

AU - Farrer, Matthew J.

PY - 2008

Y1 - 2008

N2 - Background: Overexpression of -synuclein (SNCA) in families with multiplication mutations causes parkinsonism and subsequent dementia, characterized by diffuse Lewy Body disease post-mortem. Genetic variability in SNCA contributes to risk of idiopathic Parkinson's disease (PD), possibly as a result of overexpression. SNCA downregulation is therefore a valid therapeutic target for PD. Results: We have identified human and murine-specific siRNA molecules which reduce SNCA in vitro. As a proof of concept, we demonstrate that direct infusion of chemically modified (naked), murine-specific siRNA into the hippocampus significantly reduces SNCA levels. Reduction of SNCA in the hippocampus and cortex persists for a minimum of 1 week post-infusion with recovery nearing control levels by 3 weeks post-infusion. Conclusion: We have developed naked gene-specific siRNAs that silence expression of SNCA in vivo. This approach may prove beneficial toward our understanding of the endogenous functional equilibrium of SNCA, its role in disease, and eventually as a therapeutic strategy for -synucleinopathies resulting from SNCA overexpression.

AB - Background: Overexpression of -synuclein (SNCA) in families with multiplication mutations causes parkinsonism and subsequent dementia, characterized by diffuse Lewy Body disease post-mortem. Genetic variability in SNCA contributes to risk of idiopathic Parkinson's disease (PD), possibly as a result of overexpression. SNCA downregulation is therefore a valid therapeutic target for PD. Results: We have identified human and murine-specific siRNA molecules which reduce SNCA in vitro. As a proof of concept, we demonstrate that direct infusion of chemically modified (naked), murine-specific siRNA into the hippocampus significantly reduces SNCA levels. Reduction of SNCA in the hippocampus and cortex persists for a minimum of 1 week post-infusion with recovery nearing control levels by 3 weeks post-infusion. Conclusion: We have developed naked gene-specific siRNAs that silence expression of SNCA in vivo. This approach may prove beneficial toward our understanding of the endogenous functional equilibrium of SNCA, its role in disease, and eventually as a therapeutic strategy for -synucleinopathies resulting from SNCA overexpression.

UR - http://www.scopus.com/inward/record.url?scp=58149269261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149269261&partnerID=8YFLogxK

U2 - 10.1186/1750-1326-3-19

DO - 10.1186/1750-1326-3-19

M3 - Article

C2 - 18976489

AN - SCOPUS:58149269261

VL - 3

JO - Molecular Neurodegeneration

JF - Molecular Neurodegeneration

SN - 1750-1326

IS - 1

M1 - 19

ER -